The intestinal epithelial barrier separates the host from the microbiota that is normally tolerated or ignored. The breach of this barrier results in the entrance of bacteria or bacteria-derived products into the host, accessing the host circulation and inner organs leading to the uncontrolled inflammation as observed in patients with inflammatory bowel disease (IBD), that are characterized by an increased intestinal epithelial permeability.
Introduction
The human intestine is colonized with a large consortium of microorganisms that forms the microbiota, who has developed a mutually beneficial relationship with the host during the evolution. In this relationship, the host provides a secure niche for the microbiota, whereas the microbiota provides vitamins, nutrient digestion and protection from pathogens to the host, where the microbiota resides 1 . When this beneficial relationship between the host and the microbiota is disturbed, diseases can develop, such as inflammatory bowel disease (IBD). IBD is a multifactorial chronic inflammatory disease of the intestine caused by genetic and environmental factors that occur in two major forms, Crohn's disease (CD) and ulcerative colitis (UC). Despite similarities between the two IBD forms, they are characterized by certain differences in the location and nature of inflammatory modifications. CD is a relapsing transmural inflammatory disorder that can potentially extend to any part of the gastrointestinal tract, while UC is non-transmural and is restricted to the colon. Furthermore, mutations in Nucleotide-binding oligomerization domain-containing protein 2 (NOD2), a pattern recognition receptor (PRR) that recognizes muramyl dipeptide (MDP), a component of the cell wall of most Gram-positive and -negative bacteria, is associated with CD 2 . Furthermore, Escherichia coli (E. coli), Listeria and Streptococci and their products were all found within macrophages in CD patients that have entered the host after a barrier breach 3 . When bacteria or their products enter the host during the development of CD, the immune system develops a response leading to the production of circulating antibacterial antibodies 4 . Maybe, the most convincing evidence for the role of the microbiota in the pathogenesis of IBD stems from mouse models. When animals are treated with antibiotics, or when mice are kept in germ-free (GF) conditions, the severity of the disease is reduced in most colitis models, such as in IL-10-/-mice that do not develop colitis in GF facilities 5, 6 . Furthermore, colitis also disturbs the composition of the microbiota, which is characterized by an imbalanced composition and reduced richness called dysbiosis 7 . The consequence of IBD can be an increased intestinal permeability that can lead to the entrance of microbes and microbial-derived products into the host.
In animals, the application of Dextran Sodium Sulfate (DSS) induces an intestinal epithelial breach leading to an increased permeability of the epithelial barrier 8 . Portal LPS concentrations are elevated in animals with DSS colitis 9 . Interestingly, animals lacking the C type lectin receptor specific intracellular adhesion molecule-3 grabbing nonintegrin homolog-related 1 (SIGN-R1) are protected from DSS colitis and LPS-induced endotoxemia 10 . To further disseminate into the host, bacteria or bacteria derived products have to pass the vascular barrier 11 , the peritoneal cavity, in which the small and large intestine is located, the mesenteric lymph nodes and/or the liver . Toll-like receptor 4 (TLR4) expressed by dendritic cells, macrophages, and epithelial cells recognizes LPS 15 , that requires co-receptors for appropriate binding. The acute phase protein LPS-binding protein (LBP) binds LPS to form a complex that transfers LPS to the cluster of differentiation 14 (CD14), a glycosylphosphatidylinositol-anchored membrane protein. CD14 further shuttles LPS to Lymphocyte antigen 96 or also known as MD-2, which is associated with the extracellular domain of TLR4. The binding of LPS to MD-2 facilitates the dimerization of TLR4/MD-2 to induce conformational changes to recruit intracellular adaptor molecules to activate the downstream signaling pathway 14 , which includes the myeloid differentiation primary response gene 88 (MyD88)-dependent pathway and the TIR domain-containing adaptor-inducing interferon-β (TRIF)-dependent pathway 16 . The recognition of LPS by TLR4 then activates the NF-κB pathway and induces the expression of proinflammatory cytokines, such as TNFα, IL-6, and IL-1β 17 .
In particular, when LPS is injected into animals, the concentration of LPS given to the animals, the genetic background of the animal and the diet has to be considered. High concentrations of LPS leads to a septic shock, characterized by hypotension and multiple organ failures, and finally to death 18 . Mice are less sensitive to LPS compared to humans, where LPS concentrations between 2-4 ng/kg body weight (BW) are able to induce a cytokine storm 19 . For mice, the lethal dose (LD50), which induces death in half of the mice ranges from 10-25 mg/kg BW 20 depending on the mouse strain used. For the commonly used mouse strains, C57Bl/6 and BALB/c, the lethal dose 50% (LD50) is 10 mg/kg BW. In contrast, the strains C3H/HeJ and C57BL/10ScCr are protected from LPS induced endotoxemia, which is due to mutations in Tlr4
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. Consequently, Tlr4-deficient mice are hyporesponsive to injections with LPS 22 . Other genetically modified mouse lines, such as PARP1-/-mice 23 are resistant to LPS-induced toxic shock.
The mouse model described here uses a sublethal dose of LPS administered systemically to mimic the consequences of LPS dissemination after a barrier breach of the body`s surfaces. The chosen LPS concentration (2 mg/kg BW) did not induce mortality in C56Bl/6 mice, but the induced release of pro-inflammatory cytokines.
Protocol
Mice were bred and kept under specific pathogen-free (SPF) conditions in the animal facility of Department of Biomedicine, University of Basel (Basel, Switzerland). All mouse experiments were performed in accordance with the Swiss Federal and Cantonal regulations (animal protocol number 2816 [Canton of Basel-Stadt]).
Preparation of LPS Solution
1. Open the stock of LPS purified from Escherichia coli 0111:B4 under sterile conditions and reconstitute it in water to the concentration of 5 mg/ mL. 2. Dilute the LPS stock with the sterile phosphate buffered saline (PBS) to the working concentration of 0.2 µg/µL.
Intraperitoneal Injection of LPS to Mice
1. Aspirate the LPS working solution in a 0.5 mL syringe with a 30 G needle in a laminar air flow. 2. Weigh female C57Bl/6 mice (six to 10 weeks of age) and calculate the amount of LPS that will be injected: 10 µL (2 µg)/g body weight.
NOTE: For example, if a mouse weighs 20 g, then 20 g x 10 µL = 200 µL LPS working solution needs to be injected. 3. Handle the mouse gently but firmly and restrain the animal in one hand. Ensure that the animal is able to breathe normally but not to twist and turn during the restraint. 4. Tilt the mouse nose slightly towards the floor to expose the abdomen for injection. Locate the midline of the abdomen and the injection place in the low abdomen left or right from the midline. Inject i.p. PBS instead of LPS into control mice. 5. With the free hand, inject the appropriate volume (the volume calculated in step 2.2) of the LPS working solution. Make sure that the needle has entered the peritoneal cavity as otherwise, mis-injections into the abdominal muscle layer may occur. Still, do not go too deep with the needle into the peritoneal cavity to avoid injuring inner organs located in that area. 6. Return the animal carefully to the cage with up to 5 mice per cage.
Monitor the Mice
1. Monitor the animals at the time of injection and every 2 h after the injection for 8 h for the occurrence and severity of endotoxemia. Therefore, use a score sheet ( Table 1 ) that has been adapted from a previously published manuscript 24 . 2. Score the LPS injected mice for the following parameters listed in Table 1 1. Check for the appearance of the fur which is normally smooth. If the fur appears ruffled, spiky or puffy fur which indicates discomfort and/or pain, score them as 1, 2, or 3. 2. Check for the activity of the mouse.
NOTE: Mice normally move freely around the whole cage eating, drinking, climbing, but suppressed or restricted activity could be a sign of pain. 3. Check for the level of consciousness.
NOTE: Mice are very curious, and they normally move around the cage investigating the surrounding. Lack of or reduced movement can suggest pain and discomfort. 4. Check the eyes.
NOTE: Fully open eyes are expected in healthy mice, but partially or fully closed eyes, possibly with secretion, can be an indication of pain. 5. Check for the respiration rate.
NOTE: Healthy mice usually have a normal and rapid respiration rate, a reduced respiration rate could be an indication of discomfort).
Representative Results
To mimic the consequences for the host after the entrance of bacteria or bacterial-derived products that occurs after intestinal barrier breach, LPS was injected into C57Bl/6 mice in a sublethal dose (2 µg/g body weight). Every single mouse was monitored and scored for the occurrence of endotoxemia with parameters listed in score sheet that includes, the appearance of the mice, the activity of the animals, the condition of eyes, and the respiration rate and quality ( Table 1) . The animals showed clinical signs of disease that peaked 6 to 10 h after the injection of LPS and recovered within 24 h (Figure 1) . Individual mice were sacrificed 2 h, 4 h, and 8 h after the injection of LPS. Tissue pieces were collected from spleen, liver, and colon. RNA was isolated from these organs and reverse transcribed to cDNA. The cDNA was used as a template for qPCR to determine the expression levels of Il6 (Figure 2A ) Il1b (Figure 2B) , TNFa ( Figure 2C ) and Il10 ( Figure 2D ) with primers used for the qPCR listed in Table 6 . The expression of Il6 peaked 2h after injection in spleen and colon, and 4 h after injection in the liver. Gapdh-R CCTGTTGCTGTAGCCGTATT 58 Table 6 : Primers used in the qPCR reaction. The sequence of primers used for qPCR to detect mouse cytokines and housekeeping gene Gapdh.
Discussion
This protocol mimics immunological processes that occur after the invasion by microbial-derived products. Critical steps within the protocol are the selection of the mouse line, the hygiene status of the mice, the dose of LPS, the monitoring of the animals for the occurrence of endotoxemia, and the time point of experiment termination. Most importantly, the genetic background of the mouse strain has to be considered. Different mouse strains have different susceptibility to LPS. For example, the C3H/HeJ and C57BL/10ScCr mice are resistant to LPS induced endotoxemia 21, 25 . Furthermore, the hygiene status of the animals may influence the course of endotoxemia in LPS. Specific-pathogen-free (SPF) animals are most commonly used. These mice are free from a defined list of pathogens, but the complete microbiota composition of these animals is not known 26, 27 . Sterile germ-free or axenic animals (that do not harbor a microbiota) are distinct from SPF mice 26 . Likely, the colonization of axenic animals with one microorganism or with a consortium of microorganisms (gnotobiotic animals) may influence the expression of genes, such as IL-19, after LPS injection compared to SPF animals 8 . Moreover, a score sheet has been suggested that was used as a score sheet for a sepsis model induced by injecting the fecal solution into the peritoneal cavity 24 . This sheetcan be discussed with the local animal welfare committee and may be adapted to the local needs. In particular, the criteria for termination needs to be discussed with the local animal welfare committee. This experiment had to be stopped when a score > 12 is achieved or when the maximum score for one individual parameter is reached. In this experiment, no animal out of eight animals exceeded a disease score of 12 after injection of LPS (2 µg/g body weight). In this study, results showing the expression of the cytokines Il6, Il1b, TNFa and Il10 in the liver, spleen and colon after injection of LPS are presented. The expression of Il1b, TNFa and Il10 peaked 4 h after LPS injection in spleen, liver, and colon, whereas, Il6 expression peaked 2 h after LPS injection in spleen and colon and 4 h after LPS injection in the liver. Within 8 h the expression Il6, Il1b, TNFa and Il10 returned to baseline levels in spleen, liver and colon. Disease severity peaked between 6 h and 10 h after LPS injection when the expression of Il6, Il1b, TNFa and Il10 have returned already to the baseline levels indicating that increased expression of Il6, Il1b, TNFa and Il10 occurs rapidly after LPS injection, but that the kinetics of other genes may show a different pattern after LPS injection. The expression of these cytokines could also be analyzed on the protein level in the blood of the animals by ELISA, which can be considered in addition to qPCR.
Modifications and troubleshooting of the technique are necessary in cases when a disease score > 12 is reached. Therefore, the dose of LPS has to be reduced and better adjusted to the used mouse line and the local conditions to avoid premature termination of the experiment. The manipulation of genes by deleting a given genomic region or overexpressing a gene may influence the susceptibility of mice to LPS. In preliminary experiments, the dose of LPS may be titrated to the appropriate dose to avoid unnecessary harm and death to the animals in this experiment. Of note, contamination of LPS with other bacterial-derived products and mis-injections have to be avoided. Furthermore, the kinetics of the expression of genes of interest after LPS injection needs to be determined.
Limitations are that this technique provides information on the consequences of the dissemination of microbial products into the host after an intestinal barrier breach but will not give information on events that lead to intestinal barrier breach and to causes that trigger IBD. Of course, this model is not a colitis model as the DSS colitis model, but it can be useful in addition to colitis models to study the consequence of the entrance of microbial products into the host. Furthermore, the i.p. injection of LPS will disrupt the peritoneal cavity, in which the small and the large intestines are located. This may facilitate the translocation of intestinal-derived bacterial products from the peritoneal cavity into the host.
The significance of this model is the fact it uses a defined PAMP. In other models including the i.p. injection of entire bacteria, the i.p. injection of fecal solutions 24 or the septic peritonitis models, in which peritonitis is induced by cecal ligation and puncture 28 , a vast array of microbes or their products induces disease. Furthermore, injection of LPS into mice is an uncomplicated approach and does not require surgery as in septic peritonitis induced by cecal ligation and puncture.
Further application of this model are studies that aim to investigate endotoxemia or LPS induced septicemia in any contexts characterized by the translocation of bacteria-derived products into the host, such as breach of the skin barrier or breached of the urogenital tract. In conclusion, this is a straightforward model that can be used in every laboratory setting. Depending on the local conditions, there might be adaptations to the local needs necessary. In particular, the score sheet has to be discussed with the local authorities before the experiment is performed. This approach was used to mimic consequences for the host when bacteria or bacterial-derived products enter the host after a barrier breach has occurred. This may be in particular relevant in studies examining the basis of IBD where the occurrence of an intestinal barrier breach is a common event in the pathology of the disease.
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